Venture Capital News: Somite AI Grabs $47M Series A Funding
2025-05-13
BOSTON, MA, Somite AI, a TechBio company leveraging foundation models and proprietary AI to accelerate human cell therapy development, closed its Series A funding round, raising more than $47 million.
The round was led by Khosla Ventures, with participation from SciFi VC, the Chan Zuckerberg Initiative, Fusion Fund, Ajinomoto Group Ventures, Pitango HealthTech, TechAviv, Harpoon Ventures, along with angel investors such as Dr. R. Martin Chavez (former Chairman of Recursion), and Fidji Simo (outgoing CEO of Instacart and incoming CEO of Applications at OpenAI).
Somite.ai is a venture-backed company aiming to become the OpenAI of stem cell biology, developing AI foundation models to produce human tissue for cell therapies at scale for diseases such as diabetes, obesity, and muscular dystrophies. Somite's AI platform, AlphaStem, fuels a virtuous cycle: It enables new cell therapies, generating massive data that further improve the platform, empowering even faster therapy creation with broader applications.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors